about
Lung-MAP--framework, overview, and design principlesNon-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial DesignCo-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeRociletinib in EGFR-mutated non-small-cell lung cancer.Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivoCarboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma.Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinomaHigh-dose fenretinide in oral leukoplakia.The BATTLE trial: personalizing therapy for lung cancer.Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesionsCyclin D1 and cancer development in laryngeal premalignancy patients.Gene expression profiling predicts the development of oral cancer.Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.Focus on head and neck cancer.An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene MutationsEpidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners.Optimizing biomarkers and endpoints in oral cancer chemoprevention trials.Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancyBayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer.Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance.The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.
P50
Q26786694-EB34D3BE-670D-4F68-B5E3-640360C95392Q27003440-30648181-5BD5-4D02-8B3C-6B20B0019D6BQ27345462-E276651E-1E1D-408D-A250-84DD6074752FQ27851703-260B27A7-4557-443D-A5F8-35B78B2AC6C6Q27853159-EFB78AEF-38BD-450D-A1FA-85EC44F10834Q28476362-0F269F87-028A-4596-9261-793A9C64EEE2Q30275719-5F6A28A8-E89D-4D88-BA2E-1FD5263CD040Q33343271-E1CC146F-DEF3-4088-B646-237A4361D337Q33343275-200AB855-519B-4B96-846F-660AA2C6E78EQ33368746-B4A87238-18DC-4B78-A15B-345EF4E2FCBDQ33369094-02A097E1-1969-4EBC-8924-C333FED2E307Q33377144-6A3C0031-B374-4EC6-8126-DF82849B2627Q33407021-9D65ED62-0DC3-491A-B83F-F4472A777623Q33561959-37230A51-A333-43CC-BA90-BA594ADA1209Q33976619-F5E932BF-4BEB-4508-9960-A1CE7C4BE3CDQ34010378-30BDDFD5-BAD3-4C2A-BCCA-FF4C993696F9Q34021476-C09208BB-53BE-414D-ADDF-5F8C311106CAQ34164825-AFB4B129-5556-4912-BFC4-A0D21014A122Q34275011-B0D815A3-03D4-46C6-85FC-268E06F2EA5FQ34568606-484EBDA6-375E-43BE-BEC5-1B4970F98F67Q34569485-2364BB86-335E-4629-BB95-1C8B0116AA39Q34782013-B38190DB-6226-4386-97F9-1D37E8970FE3Q35050740-BCD2EE46-A280-4721-A646-F5DE4BD2C15DQ35749406-3BD10083-ECE2-4FA6-AADD-85A8AF13255FQ35911903-049DC673-6CDA-4BED-B1C1-02C23E90642FQ36303134-4C355D84-02A6-497B-A1DF-90F76C20E582Q36535735-64A6B44A-D27C-4154-93CF-EC8F3FB2D0F8Q36542497-7C7D6E96-B045-43EB-A93C-24988915083DQ36545344-AF83DC16-5215-4079-9082-BF27B878F7E1Q36631786-10CC9E19-1D06-4E74-8F8E-C5F07757273AQ36780645-425757F7-CB64-4CA7-8DD9-33A53BFBF72CQ36842556-7770867B-DDE6-4806-99F3-DEA614C75350Q36931001-5C8231A0-B9CD-432D-A597-507217F34B16Q37104767-5FCA5E26-08C6-4B0B-B611-624D7969A725Q37238720-228124FE-188D-4F77-B657-7C500D83729EQ37349280-922EC72D-1A3F-452E-AD14-F6839A42AE8CQ38014701-491A4298-7CEB-4746-8FE2-1098EB369DB3Q38060509-4E6BB1FD-7305-4FE9-87E9-F63E65E74B0FQ38088837-CDAE92F2-DBA7-407B-ABFA-EE23534E8426Q38098659-3D636FEE-5E99-4EFB-80B7-7501BAAD0A64
P50
name
Vassiliki Papadimitrakopoulou
@en
Vassiliki Papadimitrakopoulou
@nl
type
label
Vassiliki Papadimitrakopoulou
@en
Vassiliki Papadimitrakopoulou
@nl
prefLabel
Vassiliki Papadimitrakopoulou
@en
Vassiliki Papadimitrakopoulou
@nl